Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 10, Issue 7, Pages 1105-1112Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2010.487061
Keywords
enbrel; interleukin-12; interleukin-23; psoriasis treatments; tumor necrosis factor; alpha inhibitor
Funding
- Amgen
- Astellas
- Centocor and Stiefel
- National Biologic Corporation
- Galderma Laboratories
Ask authors/readers for more resources
Importance of the field: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. Areas covered in this review: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. What the reader will gain: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. Take home message: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available